Stock Traders Purchase High Volume of Call Options on Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) was the recipient of some unusual options trading on Thursday. Investors acquired 7,425 call options on the stock. This is an increase of approximately 529% compared to the typical daily volume of 1,181 call options.

Rocket Pharmaceuticals News Roundup

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: FDA approval of KRESLADI for severe pediatric LAD‑I — regulatory green light expands Rocket’s commercial path for a first‑in‑class gene therapy for a fatal childhood disorder; approval is narrowly targeted to patients without an HLA‑matched sibling donor, and the decision creates revenue potential and clinical/regulatory validation that could benefit the company’s pipeline. Proactive: Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
• Positive Sentiment: Industry and media coverage emphasize milestone nature and platform validation — outlets note the approval could “clear the way” for future Rocket products, which supports longer‑term upside if the company executes commercially. BioSpace: Rocket’s Gene Therapy Wins FDA Greenlight
• Positive Sentiment: Analyst reaffirmation with a high price target — Chardan Capital reiterated a Buy and set an $11 target, signaling street conviction and implying substantial upside from current levels if commercialization prospects materialize. Benzinga: Chardan reaffirms Buy, $11 PT
• Neutral Sentiment: Unusually large options activity — a surge in call buying (noted the prior day) indicates speculative/short‑term trader interest around the approval news; this can amplify volatility but doesn’t directly change fundamentals. Seeking Alpha transcript and options note
• Negative Sentiment: Commercial and execution risks remain — small patient population for LAD‑I, reimbursement/pricing negotiations, manufacturing scale‑up, and post‑approval commitments (including potential confirmatory trials) could limit near‑term revenue and increase spending; these uncertainties explain why shares remain volatile and below some long‑term targets until commercial traction is shown. Reuters: Coverage of approval and market reaction

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 12,253 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,557.43. Following the completion of the transaction, the general counsel owned 683,376 shares in the company, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Gaurav Shah sold 12,279 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,643.49. Following the completion of the transaction, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at approximately $3,482,268.95. The trade was a 1.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 29,415 shares of company stock valued at $97,398 in the last quarter. 24.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. acquired a new stake in shares of Rocket Pharmaceuticals during the 2nd quarter valued at $25,000. Franklin Resources Inc. bought a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth $38,000. Sequoia Financial Advisors LLC acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter worth $42,000. CANADA LIFE ASSURANCE Co grew its holdings in shares of Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 5,926 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $40,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Price Performance

Rocket Pharmaceuticals stock traded down $0.92 during midday trading on Friday, hitting $3.77. The company’s stock had a trading volume of 23,131,093 shares, compared to its average volume of 4,085,159. Rocket Pharmaceuticals has a 12 month low of $2.19 and a 12 month high of $8.26. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $411.38 million, a PE ratio of -1.88 and a beta of 0.39. The stock’s 50-day moving average price is $4.03 and its 200-day moving average price is $3.63.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.04. During the same quarter in the prior year, the business posted ($0.62) EPS. Analysts anticipate that Rocket Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RCKT. Wall Street Zen lowered shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 8th. Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday. Morgan Stanley set a $5.00 price target on shares of Rocket Pharmaceuticals in a research note on Thursday, January 8th. Cantor Fitzgerald increased their price objective on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Finally, Lifesci Capital upgraded shares of Rocket Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Rocket Pharmaceuticals has an average rating of “Hold” and a consensus price target of $13.79.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.